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Background: Bovicin HC5 is an antimicrobial peptide that shows a broad spectrum of activity and potential for
biotechnological and therapeutic applications. To gain insight about the safety of bovicin HC5 application, the
histological and immunostimulatory effects of orally administrated bovicin HC5 to BALB/c mice were evaluated.
BALB/c mice were divided into three groups: negative control (NC group); mice given purified bovicin HC5
(Bov group); mice given ovalbumin (positive control, PC group; a murine model of enteropathy). The mice were
initially pre-sensitized, and PBS, bovicin HC5 or ovalbumin were administered for 30 days by daily gavages.
Histological and morphometric analysis were performed and the relative expression of cytokines was analyzed by
real-time RT-PCR.
Results: The oral administration of bovicin HC5 to BALB/c mice reduced weight gain and caused alterations in the
small intestine, although absorptive changes have not been detected. The number of total goblet cells and the
mucopolysaccharides production were not affected by bovicin HC5 administration. A hypertrophy of Paneth cells
and an increase in the number of mitotic cells were observed in Bov group, while the number of mast cells
remained unaltered. Increased expression of TNF-α, INF-γ and IL-12 was observed in the small intestine upon
bovicin HC5 administration.
Conclusion: Bovicin HC5 has only minor effects on intestinal permeability and did not elicit an allergenic response
upon oral administration to animal models. Considering the low in vivo toxicity of bovicin HC5, it might be a good
candidate for enteral applications.
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Bacteriocins are antimicrobial peptides produced by many
species of bacteria and some members of the Archaea
domain. Nisin, the most well-known bacteriocin, is pro-
duced by Lactococcus lactis strains and it belongs to the
lantibiotic class of bacteriocins; nisin has GRAS status
(Generally Recognized as Safe) and is currently the only
bacteriocin approved for use as a food preservative [1].
Other bacteriocins, such as pediocin PA-1/AcH and
lacticin 3147, are also commercially available, but are
marketed as fermentates of lactic acid bacteria (LAB) hav-
ing GRAS status [2].* Correspondence: hcm6@ufv.br
1Departamento de Microbiologia, Universidade Federal de Viçosa, Viçosa,
Minas Gerais, Brazil
Full list of author information is available at the end of the article
© 2013 Paiva et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe targeted mechanism of action and the relatively low
propensity to select resistant bacteria are attractive pro-
perties of the lantibiotics. Moreover, previous studies have
demonstrated the efficacy of many lantibiotics against tar-
get bacteria [3] and also the potential for biotechnological
and therapeutic applications of these peptides [4]. Despite
the good results obtained in vitro, the large scale applica-
tion of lantibiotics remains limited due to the lack of data
regarding clinical aspects, including the destiny of the
peptides after ingestion, the loss of antimicrobial activity,
the cytotoxicity and the immunostimulatory effects trig-
gered by these peptides in vivo [5].
In order to evaluate the in vivo toxicity, an antimicro-
bial peptide should be administered daily and repeatedly
to an animal model for a required period of time [6,7],
and the route of administration should be the same pro-
posed for use in vivo [8]. Because lantibiotics generallytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Gain or loss of body weight in BALB/c mice during the
experimental period. The gain/loss of weight is shown as
percentage of the animals’ weight, which was calculated comparing
the weight at the end of the experiment (day 58) to the weight at
the day of the first immunization (day 0). Each bar represents the
percentage of weight gain obtained from two independent
experiments, with the standard deviation (SD) (N = 8 animals per
group). Statistically significant differences among treatments by the
Dunn’s multiple comparison test (p < 0.05) were indicated by
different lowercase letters (“a” or “b”) above the error bars.
(NC) negative control group; (Bov) mice treated with bovicin HC5;
(PC) positive control group.
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genicity, coupling of these peptides to protein carriers or
the use of adjuvants can be useful strategies to enhance
the immunogenicity [9,10].
Bovicin HC5, a lantibiotic produced by the ruminal bac-
terium Streptococcus bovis HC5, has desirable properties,
such as broad spectrum of activity, stability to low pH and
high temperatures [11,12]. The mechanism of action of
bovicin HC5 was recently elucidated and it is based on the
specific interaction with lipid II molecule, leading to inhi-
bition of the bacterial cell wall synthesis and eventually to
pore-formation [13]. Previous results indicated that the
in vitro toxicity of bovicin HC5 against mammalian cells is
comparable to nisin [14]. Bovicin HC5 has been suggested
as a potential alternative to classical antibiotics in livestock
production and as an additive for food preservation [15,16].
To gain insight about the safety use of bovicin HC5 on
animal hosts, we analyzed the effects of orally adminis-
trated bovicin HC5 to BALB/c mice, focusing on gastro-
intestinal permeability, morphological alterations in the
GI tract and the immunostimulatory effects of the peptide.
We used a murine model of enteropathy induced by sen-
sitization to compare the effects caused by the administra-
tion of bovicin HC5.
Results
The administration of bovicin HC5 induces less weight
gain in BALB/c mice
The weight of BALB/c mice was monitored during the trial
period to verify if the sensitization followed by challenge
with bovicin HC5 or ovalbumin affected weight gain of the
animals, which could indicate clinical manifestation of al-
lergy or gastrointestinal disorders. Symptoms as diarrhea,
intestinal bleeding or rectal prolapsed were not observed.
Prior to the experiment, no significant differences were
detected among the average weight of the mice (18.5, 18.4
and 18.3 g to NC, Bov and PC groups, respectively). In the
NC group, the average mice weight ranged from 18.5 ±
0.35 g (day 0) to 20.8 ± 0.31 g (day 58), or a weight gain of
11.01% along the trial period.
Animals sensitized with bovicin HC5 or ovalbumin
gained weight only during the three initial weeks of the
experiment, before starting the oral administration of
bovicin HC5 or ovalbumin. After 58 days of experiment,
the percentage of weight gain was 0.91 and −1.8% for ani-
mals of the Bov and PC groups, respectively, which was
significantly lower compared to the NC group (p < 0.05).
There was no significant difference of weight gain between
the Bov and PC groups (Figure 1).
Gastrointestinal permeability is not altered upon oral
administration of bovicin HC5
No β-lactoglobulin (β-LG) was detected in serum sam-
ples obtained before β-LG administration or in samplesfrom the NC group after administration of β-LG. In sera
obtained from animals of the PC group, significant
amounts of β-LG were detected after 0.5, 1 and 2 h of
β-LG administration (3.47 mg ml-1, 3.53 mg ml-1 and
12.14 mg ml-1, respectively). After 5 h of administration,
β-LG could not be detected in the PC group, suggesting
that β-LG clearance required at least 5 h to occur. In the
Bov group, low concentrations of β-LG (1.08 mg ml-1)
were detected in animal sera after 5 h of β-LG adminis-
tration (Figure 2).
Oral administration of bovicin HC5 and ovalbumin induce
histological and morphometric alterations in the intestine
of BALB/c mice
No alterations were identified in the liver and heart of
animals from all the groups analyzed (data not shown).
A significant decrease in the total number of spleen cells
was observed in Bov and PC groups, when compared to
the NC group (Figure 3).
The small intestine of the NC group presented a well-
preserved villi and crypts, with intact intestinal layers
(Figure 4A and 4D). In the Bov group, the severity of the
effects varied among the animals and major alterations
were observed in the lamina propria (mild edema) and in
the apical portion of the villi, with a “worst case scenario”
being presented in Figure 4B and 4E. As expected, the ani-
mals from the PC group developed intestinal inflamma-
tion, characterized by inflammatory cell infiltration, tissue
Figure 2 Concentration of β-lactoglobulin in animal sera from
treatment groups. Upon an intragastrically dose of β-LG, blood
was collected at the indicated time points and the levels of β-LG in
mice sera were determined by FPLC. The results are shown as the
average of β-LG concentration detected in a pool of animal’s sera
from each experimental group (N = 8 mice per group), in two
independent experiments. (NC) negative control group; (Bov) mice
treated with bovicin HC5; (PC) positive control group.
Figure 4 Photomicrographs of longitudinal sections of small
intestine of the experimental groups. Jejunum segments were
collected and processed for optical microscopy analysis at the end
of the experiment (day 58) (N = 8 mice per group). (NC), negative
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of the lamina propria (Figure 4C and 4F).
Morphometric analysis of the small and large intestine
of the animals treated with bovicin HC5 or ovalbumin
showed some impairment of the intestinal structure in-
tegrity, but the severity of the alterations caused by
bovicin HC5 and ovalbumin was clearly different.
The number of PAS+ cells, which secrete only neutral
mucopolysaccharides, did not differ among the groups
(Figure 5A), and cells secreting exclusively acid mucins
(AB+ cells) were not detected. The majority of goblet cellsFigure 3 Comparison of the total number of splenocytes
among experimental groups. Data are shown as average ± SD,
from two independent experiments (N = 8 mice per group).
Statistically significant differences among treatments by the Dunn’s
multiple comparison test (p < 0.05) were indicated by different
lowercase letters (“a” or “b”) above the error bars. (NC) negative
control group; (Bov) mice treated with bovicin HC5; (PC) positive
control group.
control group, figures A and D; (Bov) mice treated with bovicin HC5,
figures B and E; (PC) positive control group, figures C and F. The
sections were stained with hematoxylin and eosin (HE; left panel) or
PAS/Alcian Blue (right panel). Abbreviations: L: lumen; EP: simple
cuboidal epithelium; BB: brush border; V: villum; LP: lamina propria;
LC: Lieberkühn crypt; Sm: submucosa; IC: inner circular muscle layer;
OL: outer longitudinal muscle layer. The asterisks indicate intraepithelial
lymphocytes; simple arrow indicates Paneth cells. Black arrow head
indicates goblet cells PAS/AB+; red arrow head indicates PAS+ cells. Right
panel – Scale bar: 100 μm; Left panel – Scale bar: 50 μm.in NC group was PAS/AB+ cells, which secrete both neu-
tral and acidic mucopolysaccharides (83% of the total
number of goblet cells). The number of PAS/AB+ cells did
not differ between the NC and Bov groups, but it was sig-
nificantly reduced in PC group (p < 0.05, Figure 5B). No
differences were observed in the total number of goblet
cells in the small intestine of Bov group, when compared
to the NC group. However, the total number of goblet
cells in the small intestine of PC group was reduced when
compared to Bov and NC groups (p < 0.05, Figure 5C).
Figure 5 Comparison of the mucopolysaccharides production
and number of total goblet cells among experimental groups.
(A) PAS+ cells; (B) PAS/AB+ cells; (C) Total number of goblet cells.
Data are shown as average ± SD, from two independent
experiments (N = 8 mice per group). Statistically significant
differences among treatments by the Dunn’s multiple comparison
test (p < 0.05) were indicated by different lowercase letters (“a” or
“b”) above the error bars. (NC) negative control group; (Bov) mice
treated with bovicin HC5; (PC) positive control group.
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of Paneth cells (Figure 6A) and an increase in the number
of mitotic cells (Figure 6B) in Bov and PC groups when
compared to the NC group (p < 0.05), although no diffe-
rences were observed between Bov and PC groups (p >
0.05). No alteration on the number of mast cells on je-
junum segments (mucosa and submucosa) was observed
between Bov and NC groups, although a significant in-
crease has been observed in PC group (p < 0.05) (Figure 7).
In PC group, the jejunum segments demonstrated a
significant increase (p < 0.05) in the number of mast cells
from the mucosa and submucosa (Figure 7), when com-
pared to Bov and NC groups.
In the small intestine of animals from the Bov group, sig-
nificant villous atrophy accompanied by villi enlargement
was observed. In PC group, the increase of the villous
diameter was even more pronounced when compared to
the Bov group (p < 0.05), although the height of the villi
was not altered, when compared to NC group (Figure 8).Figure 6 Analysis of the Lieberkuhn glands. Size of Paneth cells
(A) and number of cells in mitosis (B) at the small intestinal crypts of
the experimental groups. Data are shown as average ± SD, from two
independent experiments (N = 8 mice per group). Statistically
significant differences among treatments by the Dunn’s multiple
comparison test (p < 0.05) were indicated by different lowercase
letters (“a” or “b”) above the error bars. (NC) negative control group;
(Bov) mice treated with bovicin HC5; (PC) positive control group.
Figure 7 Number of mast cells in small intestine of the
experimental groups. Longitudinal sections from jejunum
segments were stained with toluidine blue/sodium borate (1%), and
the mast cells were counted in the mucosa and submucosa. Data
are shown as average ± SD, from two independent experiments (N
= 8 mice per group). Statistically significant differences among
treatments by the Dunn’s multiple comparison test (p < 0.05) were
indicated by different lowercase letters (“a” or “b”) above the error
bars. (NC) negative control group; (Bov) mice treated with bovicin
HC5; (PC) positive control group.
Figure 8 Morphometric analysis of the small intestinal villi.
Panel (A) and panel (B) show the height and diameter of the small
intestinal villi, respectively. Data were shown as average ± SD, from
two independent experiments (N = 8 mice per group). Statistically
significant differences among treatments by the Dunn’s multiple
comparison test (p < 0.05) were indicated by different lowercase
letters (“a”, “b” or “c”) above the error bars. (NC) negative control
group; (Bov) mice treated with bovicin HC5; (PC) positive
control group.
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with a homogenous aspect (Figure 9A and 9B). The ef-
fects of bovicin HC5 and ovalbumin were less evident in
the large intestine of the animals. No differences on
epithelium structure or cellularity were detected in Bov
group (Figure 9C), while a moderate edema at the lam-
ina propria (Figure 9D) and a significant reduction at
the mucosal thickness (Figure 10) were detected among
the animals from the PC group (p < 0.05).
Assessment of the immunostimulatory effects on spleen
and small intestine of animals treated with bovicin HC5
or ovalbumin
There was no difference in relative gene expression of
cytokines in the spleen when the means of the Bov and
NC groups were compared. Only the IL-13 mRNA ex-
pression differed among the groups, with the PC group
showing the highest expression levels in the spleen (p <
0.05) (Additional file 1). In the small intestine, the rela-
tive expression of IL-12, INF-γ and TNF-α was signifi-
cantly higher for the Bov group (p < 0.05, Figure 11A,
11B and 11E), while the IL-5, IL-13 and IL-4 mRNA
expression was significantly higher in the PC group (p <
0.05, Figure 11C, 11D and 11H). The mRNA levels of
TGF-β, IL-10 and IL-17 did not differ between the
groups (Figure 11F, 11G and 11I).
Discussion
In this study, we used a murine model of food-induced
enteropathy in order to compare the morphological and
immunostimulatory effects of the orally administeredbovicin HC5. In our positive control group, the break-
down of mucosal tolerance was obtained by oral adminis-
tration of the non-tolerogenic antigen ovalbumin (OVA).
OVA has become a reference protein for immunological
and biochemical studies, being widely used as an antigen
for studying allergic diseases in mice [17].
The model used to induce food enteropathy worked
properly, and an inflammatory reaction was developed
in the small intestine. OVA administration altered the
small intestinal architecture, increased protein permeabi-
lity, caused edema and decrease the mucosal thickness in
the large intestine. In contrast, upon oral administration
of bovicin HC5, only minor histological alterations indica-
tive of inflammation or alterations on permeability were
observed, although an atrophy of the villi and destruction
of the apical portion of the villi were detected in some re-
gions of the small intestine.
The degree of impairment of the small intestine could
explain the differences observed in weight gain between
Figure 9 Photomicrographs of longitudinal sections of large intestine of the experimental groups. Large intestine segments were
collected and processed for optical microscopy analysis at the end of the experiment (day 58) (N = 8 mice per group). (NC), negative control
group, figures A and B; (Bov) mice treated with bovicin HC5, figure C; (PC) positive control group, figure D. The sections were stained with
hematoxylin and eosin (HE; figure A) or PAS/Alcian Blue (figures B-D). Abbreviations: EP: simple cuboidal epithelium; LP: lamina propria; MT:
mucosal thickness; E: edema; ML: muscle layer. Red arrow head indicates goblet cells. Scale bar = 200 (figure A) or 100 μm (figures B, C and D).
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these alterations may have influenced the absorption of
nutrients. Saldanha et al. [18] reported that BALB/c mice
previously sensitized lost weight after challenging with
OVA, which remained until the end of the experiment.
In normal conditions, the number of mast cells in the
intestine is relatively constant, but hyperplasia can be
observed during inflammatory reactions or during stages
of remodeling/repair of inflammatory disorders [19]. As
a result of the food enteropathy developed upon admin-
istration of OVA, we observed increased number of mast
cells in the small intestine of PC group. However, no al-
terations were observed in the mast cell population from
the Bov group.Bacterial products or cell components may induce
metaplasia, proliferation and hypersecretion of goblet cells
[20]. In this study, animals treated with OVA showed re-
duced number of goblet cells in the small intestine, and a
reduction in the secretion of acidic and neutral mucins. In
contrast, the administration of bovicin HC5 did not alter
the total number or the pattern of goblet cell secretion.
The mucus protects the intestinal wall by limiting the ab-
sorption of antigens, and therefore, the hypersecretion of
mucopolysaccharides was expected at the PC group, as a
characteristic of allergic inflammation and as a result of
increased IL-13 expression [21]; therefore, the reduction
in the number of cells responsible for mucus secretion
observed in PC group may not be related to the reduction
Figure 10 Comparison of the mucosal thickness of the large
intestine among the experimental groups. Data are shown as
average ± SD, from two independent experiments (N = 8 mice per
group). Statistically significant differences among treatments by the
Dunn’s multiple comparison test (p < 0.05) were indicated by
different lowercase letters (“a” or “b”) above the error bars.
(NC) negative control group; (Bov) mice treated with bovicin HC5;
(PC) positive control group.
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fields resulting from the destruction of the villi observed
in PC group.
Similar to goblet cells, Paneth cells also play an import-
ant role in host intestinal defense mechanisms, contribu-
ting to the maintenance of the gastrointestinal barrier by
secreting antimicrobial peptides and other compounds in
response to bacteria and bacterial antigens [22,23]. The
presence of antigens in the gastrointestinal tract also influ-
ence the expression and activity of key proteins involved
in the regulation of cell proliferation [24]. Hypertrophy of
Paneth cells and increased mitotic activity were observed
in Bov and PC groups, indicating that despite the loss of
villi architecture, secretion of antimicrobial compounds
and tissue repair systems remained active, probably as a
response to the injuries caused by bovicin HC5 and OVA
in the small intestine.
Our results indicate that the effects of bovicin HC5
and ovalbumin administration are more pronounced in
the intestine, which can explain the significant reduction
in spleen cellularity observed in Bov and PC groups: im-
mune cells probably migrated from the spleen to the in-
testine, where the main effects were observed.
OVA administration modulated the gut mucosal im-
munity in BALB/c mice towards significant TH2-polarized
response, increasing the relative expression of IL-4, IL-5
and IL-13 mRNA. Goya et al. [25] also observed increased
mRNA levels of the TH2 cytokines IL-4, IL-5 and IL-13, as
well as a decrease of INF-γ expression in the lungs of
OVA-treated mice. A down modulation of regulatory
mechanisms, with reduction of TGF-β and IL-10 expres-
sion, may be involved in the development of food allergy[26], but this pattern of cytokine expression, although
expected, was not observed in this study.
The modulation of the host immune system induced
by bacteriocins is a phenomenon much less understood
when compared to other peptides or proteins, such as
proteins extracted from mushrooms (such as LZ-8
(13 kDa) [27], Fip-vvo (15 kDa) [28] and FIP-fve (114
aa) [29]) and host-defense peptides [30,31].
In contrast to the TH2-polarized response elicited by
OVA, higher mRNA expression for the TH1 cytokines
TNF-α, IL-12 and INF-γ were observed in the intestine
of bovicin HC5-fed mice. Liu et al. [32] also demon-
strated significant induction of IFN-γ after administra-
tion of the yam tuber storage protein dioscorin. Human
cathelicidin LL-37 modulated the activity of IFN-γ on a
variety of cell types [33], and pre-treatment with LL-37
induced IFN-γ production by monocytes, enhancing
monocyte-derived dendritic cell functions, such as IL-12
secretion and TH1-polarized co-stimulatory activity [34].Conclusions
In the present work, for the first time, the effects of
the oral administration of bovicin HC5 to an animal
model were described. The bovicin HC5 concentration
administrated to the animals (micromolar range) was
greater than the quantities required for in vitro anti-
microbial activity (nanomolar range). We have previ-
ously demonstrated that bovicin HC5, in higher con-
centrations, was able to permeabilize membranes in an
unspecific way [13], but one should bear in mind that
antimicrobial peptides can also modulate the microbial
community composition in the intestine which could
explain the partial destruction of small intestine cells
caused by bovicin HC5 administration. Nonetheless, the
impairment of the intestinal cells induced by bovicin HC5
neither altered the gut permeability nor was typical of an
enteropathy process. Regarding the immunostimulatory
effects, the results confirmed that bovicin HC5 was able
to stimulate the immune system of BALB/c mice at local
level (gut immune system), by influencing the cytokine re-
lease towards TH1-polarized response.
Proper pharmacokinetic studies will be needed to de-
termine if bovicin HC5 can resist passage through the
adverse conditions in the GI tract (low pH, presence
of peptidolytic and proteolytic enzymes), but it should
be noted that animals treated with bovicin HC5
showed more pronounced effects in the intestine com-
pared to the animals in the negative control groups.
These results suggest that the oral administration of
bovicin HC5 might be a promising strategy to control
microbial infections, manipulate microbial community
composition or modulate immunological responses in
the GI tract of the host animal.
Figure 11 Cytokine production in small intestine of five-week old female BALB/c mice treated with bovicin HC5 or ovalbumin. The
relative expression of IL-12p40 (A), IFN-γ (B), IL-5 (C), IL-13 (D), TNF-α (E), TGF-β (F), IL-10 (G), IL-4 (H) and IL-17 (I) mRNA was determined by real
time-PCR and calculated by reference to the β-actin in each sample, using the threshold cycle (Ct) method. Results are shown as the mean value
± SD of duplicate samples from three independent mice within the NC, Bov and PC groups. Differences among treatments were indicated by
different lowercase letters and were considered statistically significant by the Bonferroni multiple comparison test (p < 0.05). (NC) negative control
group; (Bov) mice treated with bovicin HC5; (PC) positive control group.
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Streptococcus bovis HC5 and bovicin HC5
Streptococcus bovis HC5 growth and bovicin HC5 ex-
traction were performed as previously described [11].
Purification of bovicin HC5 was performed by reversed
phase-HPLC [13] and the purity of bovicin HC5 was
confirmed by electrospray mass spectrometry to be al-
ways greater than 95%.
Bovicin HC5 stock solutions (1 mg ml-1 in PBS (10 mM,
pH 7.2)) were stored at −20°C until use. Protein concen-
tration was determined using a bicinchoninic acid protein
assay (Pierce Chemical Corp., Bonn, Germany), with bo-
vine serum albumin as the standard.
Experimental animals
The BALB/c mice used in this study were housed in an
animal facility at the Universidade Federal de Viçosa,according to standards and guidelines as set forth in the
Animal Welfare Legislation, the Guide for the Care and
Use of Laboratory Animals, the Association for the
Assessment and Accreditation of Laboratory Animal
Care (AAALAC) and the National Council for Animal
Experimentation Control (CONCEA), following ap-
proval by the Institutional Animal Care and Use Com-
mittee (IACUC) of the Universidade Federal de Viçosa
under the protocol number CEUA/UFV 97/2011.
Five-week-old female BALB/c mice were randomly di-
vided into three experimental groups: Group 1, untreated
mice (negative control, NC group); Group 2, mice given
purified bovicin HC5 (Bov group); Group 3, mice given
ovalbumin (Sigma Chemicals Co., St. Louis, MO, 99% of
purity) (positive control, PC group). Two independent ex-
periments were performed and a total number of eight an-
imals were used per experimental group.
Table 1 Sequences of sense (S) and antisense (AS) primers
used for real time-RT-PCR analysis (18)
Primers Sequences
β-actin S 50 AGC TGC GTT TTA CAC CCT TT 30
β-actin AS 50 AAG CCA TGC CAA TGT TGT CT 30
IL-10 S 50 TGG ACA ACA TAC TGC TAA CC 30
IL-10 AS 50 GGA TCA TTT CCG ATA AGG CT 30
IL-4 S 50 CTG ACG GCA CAG AGC TAT TGA 30
IL-4 AS 50 TAT GCG AAG CAC CTT GGA AGC 30
IL-5 S 50 GAG GTT ACA GAC ATG CAC CAT T 30
IL-5 AS 50 TCA GTT GGT AAC ATG CAC AAA G 30
IL-13 S 50 ACC AAC ATC TCC AAT TGC AA 30
IL-13 AS 50 ATG CAA TAT CCT CTG GGT CC 30
TNF-α S 50 TGT GCT CAG AGC TTT CAA CAA 30
TNF-α AS 50 CTT GAT GGT GGT GCA TGA GA 30
IL-12 p40 S 50 AGC ACC AGC TTC TTC ATC AGG 30
IL-12 p40 AS 50 GCG CTG GAT TCG AAC AAA G 30
IFN-γ S 50 GCA TCT TGG CTT TGC AGC T 30
IFN-γ AS 50 CCT TTT TCG CCT TGC TGT TG 30
TGF-β S 50 GCT GAA CCA AGG AGA CGG AAT 30
TGF-β AS 50 GCT GAT CCC GTT GAT TTC CA 30
IL-17 S 50 GCT CCA GAA GGC CCT CAG A 30
IL-17 AS 50 CTT TCC CTC CGC ATT GAC A 30
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previously established protocols [18]. Mice from the Bov
group were subcutaneously sensitized with bovicin HC5
(4 μg/g animal weight/day or approximately 70 μg/animal
[35]), while animals from the PC group were sensitized
with ovalbumin (100 μl of a 1 mg ml-1 stock solution in
sterile ultrapure water, or 100 μg OVA/animal). Aluminum
hydroxide was used as adjuvant (50 μl; 20 mg ml-1 stock
solution in sterile saline) at the first sensitization (day 0).
After three weeks, each mouse group was subcutaneously
boosted (without the use of adjuvant) with the respective
substances (second sensitization, day 21). The NC group
was sensitized with sterile PBS (10 mM, pH 7.2), using the
same procedure described above.
PBS, bovicin HC5 or ovalbumin (100 μl) were admin-
istered without adjuvant to the NC, Bov and PC groups,
respectively, by daily gavages (18-gauge stainless steel
feeding needles). Oral administration started one week
after the second sensitization (day 28) and continued for
30 days uninterruptedly (day 58). The mice were weekly
weighted and behavior, general appearance and adverse
reactions were monitored daily.
Gut permeability
The gut permeability was determined by the uptake of
β-lactoglobulin (β-LG) following challenge ([36], withmodifications]). At the end of the trial period (day 58), the
animals of the NC, Bov and PC groups, were orally chal-
lenged with 200 μl of the respective samples (PBS, bovicin
HC5 or ovalbumin). After thirty minutes, the animals re-
ceived an oral dose of β-LG (200 μl; 100 mg ml-1 solution
in distilled water) (Sigma Chemicals Co., St. Louis, MO,
90% of purity).
Blood samples were collected from the orbital plexus
under light isoflurane anesthesia, after 0.5, 1, 2 and 5 h of
the β-LG administration. The samples were kept at room
temperature for 2 hours, and the sera were centrifuged
(EppendorfW, Centrifuge 5415C, Hamburg, Germany) at
12,000 × g, 5 min, room temperature. Sera were used for
the quantification of β-LG by FPLC, using a cationic
change column (Mono Q HR 5/5). The column was equili-
brated with buffer A (20 mM Tris) and the β-LG was
eluted with a linear gradient of 25 to 50% buffer B (20 mM
Tris, 1 M NaCl), 22°C, and flow rate of 1 ml min-1. Ab-
sorbance was monitored at 220 and 280 nm.
The concentration of β-LG in animal sera was deter-
mined using a calibration curve with known concentra-
tions of β-LG (0; 6.25; 12.5; 25.0; 50.0 mg ml-1) mixed to
pre-immune serum of the animals from each group. The
pre-immune serum corresponded to the sera collected
prior to the initial sensitization procedure. Serum sam-
ples before β-LG administration were used as negative
control. All analyses were performed in duplicate.
Histological and morphometric analysis
On day 58 the heart, liver, spleen and gut of the all the mice
were aseptically collected, washed in PBS buffer (10 mM,
pH 7.2), fixed in Carson formalin solution [37], dehydrated
and embedded in resin (HistoresinW, Leica). Transverse and
longitudinal, 3 μm thick tissue sections were obtained and
stained with hematoxylin and eosin (H&E), toluidine blue/
sodium borate (1%) or with Alcian Blue (pH 2.5) combined
with periodic acid-Schiff (PAS) [38], depending on the
histological analysis that would be performed.
Ten fields of longitudinal sections stained with H&E
were randomly selected and visualized with a 10× ob-
jective lens in order to perform the morphological ana-
lysis of the organs selected (villi height and width were
determined from an area of 17 mm2 per animal; for mu-
cosal thickness, an average of twenty measurements
were obtained from each animal). The spleen cells were
counted using ten fields of longitudinal sections visual-
ized with a 40× objective lens, in an area of 0.23 mm2
per animal. For quantitative and qualitative analysis of
goblet cells, ten fields of longitudinal sections (area of
1 mm2) stained with Alcian Blue-PAS were randomly
selected and visualized with a 20× objective lens; the
mucins produced by goblet cells were identified by dif-
ferential staining (acid mucins in blue, neutral mucins in
red, and mixed acid and neutral mucins in purple). The
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stained with toluidine blue/sodium borate (1%) and visu-
alized with a 40× objective lens; an area equivalent to 20
jejunum villi (mucosa and submucosa) was evaluated for
each animal.
Digital images were captured with a light microscope
(Olympus AX 60), coupled to a digital camera (Q-Color 3,
Olympus). The morphometric analyzes were performed
with the image analysis program Image Pro Plus 4.0 for
Windows (Media Cybernetics). The results were shown as
mean values ± standard error of the mean.
Analysis of relative gene expression by real-time PCR
The whole spleen and jejunum segments (100 mg of tissue)
were aseptically removed, washed in sterile PBS (10 mM,
pH 7.2), and individually manipulated. Cells obtained from
the spleen were washed with saline (0.85%), centrifuged
at 7,500 × g for 5 min (EppendorfW, Centrifuge 5415C,
Hamburg, Germany), at room temperature, and the eryth-
rocytes were lysed using a hemolytic solution (155 mM
NH4Cl, 10 mM KHCO3, pH 7.2). The splenocytes were
centrifuged again and the supernatant was discarded. A
jejunum segment of 6 cm was removed and washed three
times with saline (0.85%), for removal of waste.
The splenocytes and jejunum segments were homoge-
nized in Tri Reagent (SigmaW) to isolate total RNA, follo-
wing the manufacturer’s instructions. RNA yield was
analyzed spectrophotometically at 260 nm (Ultraspec 3000,
Pharmacia Biotech, Piscataway, NJ). From each group (NC,
Bov and PC), three samples from different animals show-
ing highest RNA yield were chosen for cDNA synthesis.
Complementary DNA (cDNA) was synthesized through
a RT reaction (M-MuLV reverse transcriptase, Promega),
according to the manufacturer’s instructions. Real-time
RT-PCR was conducted with a final volume of 25 μL
containing 2.5 ng of cDNA, SYBR-green PCR Master Mix
(Applied Biosystems, Warrington, UK), oligo(dT) cDNA as
the PCR template, and 450 nM specific primers. Real-time
RT-PCR was performed on the Gene AmpW5700 Sequence
Detection System Version 1.3 (Applied Biosystems) and
the cycling parameters used were 95°C for 10 min, 40 cycles
at 94°C for 1 min, 56°C for 1 min, and 72°C for 2 min,
followed by the standard denaturation curve. The se-
quences of murine primers used in this study (Table 1)
were previously described [9].
The results were demonstrated as relative level of gene
expression in the experimental group, by reference to
the β-actin gene in each sample, using the cycle thresh-
old (Ct) method. Measurements were conducted in du-
plicates and the fold increase expression was calculated
by using the expression 2^DCt, according to the instruc-
tions from Applied Biosystems User’s Bulletin #2 (P/N
4303859). Results were shown as mean values ± standard
deviation.Statistical analysis
The means of the groups were evaluated by analysis of vari-
ance (ANOVA) followed by the Dunn’s or Bonferroni’s post
test. A probability value of less than 0.05 was considered
statistically significant, and all the comparisons were
performed using the GraphPad Prism 5.00 software
(GraphPad Software, San Diego California, USA).
Additional file
Additional file 1: Cytokine production in spleen of five-week old
female BALB/c mice treated with bovicin HC5 or ovalbumin. The
relative expression of IL-12p40 (A), IFN-γ (B), IL-5 (C), IL-13 (D), TNF-
.alpha; (E), TGF-β (F), IL-10 (G), IL-4 (H), IL-17 (I) mRNA was determined by
real time-PCR and calculated by reference to the β-actin in each sample,
using the threshold cycle (Ct) method. Results are shown as the mean
value ± SD of duplicate samples from three independent mice within the
NC, Bov and PC groups. Differences among treatments were indicated by
different lowercase letters and were considered statistically significant by
the Bonferroni multiple comparison test (p < 0.05). (NC) negative control
group; (Bov) mice treated with bovicin HC5; (PC) positive control group.
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